Abstract:Background and objective: Noninvasive non-alcoholic steatohepatitis (NASH) assessment is a clinical challenge to the management of non-alcoholic fatty liver disease. We aim to develop diagnostic models based on sequential ultrasound molecular imaging (USMI) for the noninvasive identification of NASH in mouse models. Methods: Animal experiments were approved by the Animal Ethics Committee of South China Agricultural University. Forty-nine C57BL/6 mice were divided into normal control, non-alcoholic fatty liver, NASH, and hepatitis groups. Sequential USMI was implemented using CD36-targeted microbubbles (MBs-CD36) and intercellular adhesion molecule-1 (ICAM-1)-targeted microbubbles (MBs-ICAM-1) to visualize hepatic steatosis and inflammation. The targeting signal of USMI was quantified as the normalized intensity difference (NID) with the destruction-replenishment method. Correlation analysis was conducted between the NID-MBs-CD36 and pathological steatosis score and between the NID-MBsICAM-1 and pathological inflammation score. Finally, diagnostic models combining NID-MBs-CD36 with NID-MBs-ICAM-1 were established for NASH diagnosis. Results: MBs-CD36 and MBs-ICAM-1 were successfully prepared and used for sequential USMI in all mice. NID-MBs-CD36 values increased with the progression of steatosis, while NID-MBs-ICAM-1 values increased in parallel with the progression of inflammation. A strong positive correlation was identified between NID-MBs-CD36 and pathological steatosis grade (rs = 0.9078, P < 0.0001) and between NID-MBs-ICAM-1 and pathological inflammation grade (rs = 0.9071, P < 0.0001). Among various sequential USMI-based diagnostic models, the serial testing model showed high diagnostic performance in detecting NASH, with 95% sensitivity, 97% specificity, 95% positive predictive values, 97% negative predictive values, and 96% accuracy. Conclusions: Sequential USMI using MBs-CD36 and MBs-ICAM-1 allows noninvasive grading of hepatic steatosis and inflammation. Sequential USMI-based diagnostic models hold great potential in the noninvasive identification of NASH. (c) 2023 The Third Affiliated Hospital of Sun Yat-sen University. Publishing services by Elsevier B. V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

The Significance of IL-28B and CK-18 M30 Levels in the Diagnosis of Non-Alcoholic Steatohepatitis in SD Rats.

Expressions of Key Regulatory Genes of the Lipid Metabolism in Livers During the Development of Rat Non-alcoholic Fatty Liver Disease

Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis

Serum CK 18-M30 Reflect Liver Pathological Severity During NAFLD Progression in a Rat Model

IDDF2022-ABS-0120 Hepatocyte Apoptosis Fragment Product Cytokeratin-18 M30 and Non-Alcoholic Steatohepatitis Risk Prediction: an International Registry Study

Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study

Circulating MicroRNAs As Potential Biomarkers for Alcoholic Steatohepatitis.

Clinical value of Serum CK-18 M30 levels in patients with nonalcoholic steatohepatitis

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Sequential Ultrasound Molecular Imaging for Noninvasive Identification and Assessment of Non-Alcoholic Steatohepatitis in Mouse Models

Combined and Sequential Non-Invasive Approach to Diagnosing Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease and Persistently Normal Alanine Aminotransferase Levels.

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Proteomic Analysis of Liver Mitochondria from Rats with Nonalcoholic Steatohepatitis

Disease-specific Mir-34A As Diagnostic Marker of Non-Alcoholic Steatohepatitis in a Chinese Population.

Analysis of Non‑alcoholic Fatty Liver Disease Microrna Expression Spectra in Rat Liver Tissues.

Technical Acoustic Measurements Combined with Clinical Parameters for the Differential Diagnosis of Nonalcoholic Steatohepatitis

Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease.

A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease.

Serum Lipocalin-2 is a Potential Biomarker for the Clinical Diagnosis of Nonalcoholic Steatohepatitis

Integrating Multi-Omics Reveals Crucial Biomarkers in Non-Alcoholic Fatty Liver Disease